Please login to the form below

Not currently logged in
Email:
Password:

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

He also takes up the CSO role at the UK biotech

Kunway ShailubhaiLondon, UK-based biotechnology group Tiziana Life Sciences has appointed its non-executive director Dr Kunwar Shailubhai as chief executive officer and chief scientific officer.

He has 30 years’ experience in research and development specifically in gastrointestinal disorders, inflammatory diseases and cancers, and previously co-founded Synergy Pharmaceuticals and served as its chief scientific officer.

Shailubhai has also previously served at Callisto Pharmaceuticals, Monsanto Company and as a senior staff fellow at the National Institutes of Health (NIH).

He said: “This is a crucial time to be taking on this new role with Tiziana Life Sciences in what is one of the most vital yet underdeveloped research areas.

“NASH affects more than three million people in the UK alone and there is no cure, and now we have the team and the approach necessary to make important steps to manage this disease.”

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment available to sufferers.

Gabriele Cerrone, executive chairman at Tiziana Life Sciences, said: “Having Shaliubhai as our CEO demonstrates our commitment to put our research first and his expertise at some of the top pharmaceutical companies globally means Tiziana Life Sciences can go from strength to strength.

“In particular, his experience shows he knows what it takes to shepherd research from inception to FDA approval and I know his passion for this area of work will pay off.”

13th June 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....

Infographics